Trial Profile

Immunotherapy With CD19/22 CAR Redirected T-cells for High Risk, Relapsed Paediatric CD19+ and/or CD22+ Acute Lymphoblastic Leukaemia and Other Haematological Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obecabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
Indications Burkitt's lymphoma; Haematological malignancies; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use
Acronyms CARPALL

Most Recent Events

02 Apr 2025 Planned number of patients changed from 33 to 50.
02 Apr 2025 Planned End Date changed from 31 Dec 2028 to 31 Dec 2041.
02 Apr 2025 Planned primary completion date changed from 31 Dec 2028 to 31 Dec 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com